Document Type
Article
Publication Date
7-12-2021
ISSN
1537-6591
Publisher
Oxford University Press
Language
en-US
Abstract
In 2010, the Infectious Diseases Society of America called for 10 new antibiotics by 2020 [1]. This goal was achieved in terms of the number of drug approvals, but actual patient access requires commercial launches in many countries, which itself requires sustainable commercial markets. Prior work has described limited access to new antibacterials in low- and middle-income countries (LMICs), in part due to the inability of many to afford these drugs [2]. This study examines patient access for new antibacterials in the G7 and 7 other high-income countries in Europe, to better understand other barriers to patient access to effective antibacterial therapy.
Recommended Citation
Kevin Outterson, Ebiowei S. Orubu, Muhammad H. Zaman, John Rex & Christine Årdal,
Patient access in fourteen high-income countries to new antibacterials approved by the FDA, EMA, PMDA, or Health Canada, 2010-2020
,
in
Clinical Infectious Diseases
(2021).
Available at:
https://scholarship.law.bu.edu/faculty_scholarship/1340
Included in
Agency Commons, European Law Commons, Food and Drug Law Commons, Health Law and Policy Commons, International Law Commons
